Logo Medical Science Monitor

Call: +1.631.470.9640
Mon - Fri 10:00 am - 02:00 pm EST

Contact Us

Logo Medical Science Monitor Logo Medical Science Monitor Logo Medical Science Monitor

01 February 2012: Basic Research  

Determination of PKC isoform-specific protein expression in pulmonary arteries of rats with chronic hypoxia-induced pulmonary hypertension

Yiwei Shi BCEF , Chen Wang AFG , Song Han BC , Baosen Pang BC , Nan Zhang CE , Jun Wang F , Junfa Li ACDEFG

DOI: 10.12659/MSM.882458

Med Sci Monit 2012; 18(2): BR69-75

0 Comments

Background

Pulmonary hypertension (PH) is characterized by high pulmonary arterial pressure, increased pulmonary vascular resistance, right ventricular (RV) hypertrophy, and RV failure [1–3]. The pathogenesis of PH remains unclear, but is probably mediated by hypoxia. Hypoxic exposure induces a selective pulmonary arterial vasoconstriction and an increase in pulmonary arterial pressure [4]. When hypoxic pulmonary vasoconstriction (HPV) is persistent, pro-proliferative signals are activated in vascular cells, which leads to vascular remodeling and chronic hypoxic PH [5]. Pulmonary vascular remodeling is characterized by intimal thickening, medial smooth muscle cell (SMC) hypertrophy and hyperplasia, adventitial fibroblast proliferation, and matrix protein synthesis [6,7]. The magnitude of the fixed structural changes depends on many factors, including developmental stage, genetic factors and type of insult. Protein kinase C (PKC) is an important signaling, intermediate in many of the vascular responses such as contraction and growth, and may play a key role in chronic hypoxic PH [8].

The PKC family of serine/threonine protein kinases is involved in multiple biochemical processes, including cell growth, differentiation and transformation [9,10]. So far, at least 10 PKC isoforms have been identified in mammals and classified into 3 subgroups based on their molecular structures and sensitivity to activators: conventional PKC (cPKCα, βI, βII and γ), requiring both Ca2+ and diacylglycerol for activation; novel PKC (nPKCδ, ɛ, η and θ); and atypical PKC (aPKCι/λ and ζ) [11]. Numerous PKC isozymes are expressed in pulmonary vascular media smooth muscle and adventitial fibroblasts [12,13], and their activations are generally marked by its translocation from the cytosolic fraction to the particulate or membrane-related fraction [14,15].

PH is a major cause of disability in patients with chronic lung, heart and sleep disorders, and supplemental oxygen and supportive care are the only treatments currently available. PKC-based therapy might be a complementary therapeutic tool, but the role of individual PKC isoforms in the regulation of chronic hypoxic PH remains unclear. Previous studies have suggested that PKC mediates hypoxia-induced proliferation and growth of pulmonary artery adventitial fibroblasts and smooth muscle cells [16–19]. Ca2+-dependent cPKCα and β expressed in pulmonary artery smooth muscle cells (PASMCs) are particularly important in their hypoxic growth and, ultimately, the development of chronic hypoxic PH [17,20,21]. Das et al. found that bovine pulmonary artery adventitial fibroblasts expressed cPKCα, βI and βII, nPKCδ and ɛ, and aPKCζ, but only cPKCβI and aPKCζ activations were associated with the exaggerated growth responses of pulmonary artery adventitial fibroblasts under chronic hypoxia condition [16,22]. However, Short et al. found that aPKCζ attenuates hypoxia-induced proliferation of fibroblasts by regulating MAP kinase phosphatase-1 (MKP-1) expression [23].

Unfortunately, most of the experiments were carried out in vitro and some results are contradictory. The systematic investigation of PKC isoform-specific protein expression and activation in pulmonary vascular regions were rare in whole animal models with chronic hypoxia. Therefore, the primary aim of this study was to determine the PKC isoform-specific involvement in the development of hypoxic PH by observing their protein expression and membrane translocation in pulmonary arteries of hypoxia-induced PH rats.

Material and Methods

ANIMALS AND HYPOXIC EXPOSURE:

All procedures conducted in this study were approved by the Animal Care and Use Committee of Capital Medical University and were consistent with the NIH Guide for the Care and Use of Laboratory Animals (NIH Publications No. 80-23). Specific pathogen-free adult male Sprague-Dawley (SD) rats, weighing 200–250 g, were exposed for the specified time periods (1, 3, 7, 14 and 21 d [days]) to normobaric hypoxia (10% oxygen) in a ventilated Plexiglas chamber while age- and weight-matched control rats were maintained in a 21% oxygen environment (n=12 per group).

To establish the hypoxic conditions as previously reported [24], the chamber was flushed with a mixture of oxygen and nitrogen from high-pressure cylinders, and an oxygen analyzer was used to monitor the chamber environment. CO2 was removed with soda lime, excess humidity was prevented by Drierite granules, and boric acid was used to keep ammonia levels within the chamber to a minimum. The chamber was opened every other day for 30 min (minutes) to clean the cages and replenish food and water.

HEMODYNAMICS AND ESTIMATION OF RV HYPERTROPHY:

At the end of the hypoxic exposure, the animals were anesthetized with pentobarbital sodium (50 mg/kg, i.p.), and a 1.4F microtip pressure transducer (SPR-671; Millar Instruments; Houston, TX, USA) was inserted into the right ventricle (RV) through the jugular vein for hemodynamic measurements. RV systolic pressure (RVSP, an indirect index of pulmonary artery pressure) was measured with a polygraph system (PowerLab; AD Instruments, Australia). The RV was dissected from the left ventricle (LV) and the septum (S), and weighed separately to determine the ratio of RV to LV plus S, RV/(LV+ S) as RV hypertrophy [25].

SUBCELLULAR FRACTIONATION AND WHOLE TISSUE HOMOGENATE PREPARATIONS:

The animals were anesthetized with pentobarbital sodium (50 mg/kg, i.p.), exsanguinated in the hypoxic chamber, and the lungs were removed from the thoracic cavity. Under a microscope, pulmonary arteries, including the main trunk plus the right and left branches, were isolated in ice-cold phosphate-buffered saline (PBS) containing 120 mM NaCl, 2.7 mM KCl, and 10 mM phosphate buffer, and were quickly frozen in liquid nitrogen for later analysis.

As in our previous reports [15,26], the frozen samples were placed into 100 μl freshly prepared homogenization buffer A (50 mM Tris-Cl, pH 7.5, 2 mM DTT, 2 mM EDTA, 2 mM EGTA, 5 mg/ml each of leupeptin, aprotinin, pepstatin A and chymostatin, 50 mM potassium fluoride, 50 μM okadaic acid, 5 mM sodium pyrophosphate) and homogenized. The homogenate was centrifuged at 30 000 g for 30 min, and the supernatant was collected as cytosolic fraction. The pellet was further solubilized in 100 μl homogenization buffer B (buffer A containing 0.5% Nonidet P-40) before being sonicated and centrifuged at 30 000 g for 30 min again, and the resulting supernatants were taken as particulate fractions. Both fractions were prepared for PKC isoform-specific membrane translocation analysis. To determine PKC isoform-specific protein expression levels, frozen pulmonary arteries were homogenized in 250 μl homogenization buffer C (buffer A containing 2% SDS) and sonicated to dissolve completely as the whole tissue homogenate. The protein concentration was determined by the BCA protein assay (Pierce Company, Rockford, IL, USA).

WESTERN BLOT ANALYSIS:

As described previously [26,27], equal amounts of vascular protein (50 μg from either cytosolic or particulate fractions, and 20 μg from whole tissue homogenate) per lane were loaded on 10% SDS-PAGE gels. After separation, the proteins were transferred onto polyvinylidene difluoride (PVDF) membrane (GE Healthcare, Buckinghamshire, UK) at 4°C. After several rinses with TTBS (20 mM Tris-Cl, pH7.5, 0.15 M NaCl and 0.05% Tween-20), the transferred PVDF membrane was blocked with 10% non-fat milk in TTBS for 1 h (hour) and incubated with the primary rabbit polyclonal antibodies against cPKCα, βI, βII and γ, nPKCδ, ɛ, η and θ, and aPKCι/λ and ζ (Santa Cruz Biotechnology Inc., CA, USA) at 1:5000 dilution for 3 h. To verify equal loading of protein, the blots were stripped by incubating the membranes for 45 min in stripping buffer containing 62.5 mM Tris-Cl (pH 6.7), 2% SDS and 100 mM 2-mercaptoethanol at 55°C and reprobed with primary mouse monoclonal antibody against β-actin (Sigma-Aldrich Company, St. Louis, MO, USA). The horseradish peroxidase-conjugated goat anti-rabbit or anti-mouse IgG (Stressgen Biotechnologies Corporation, Victoria, BC, Canada) were used as second antibodies at a 1:3000 dilution for 1 h incubation. Following incubation with the primary and secondary antibodies, the Enhanced Chemiluminescence (ECL) kit (GE Healthcare, Buckinghamshire, UK) was employed to detect the signals.

To quantify membrane translocation, the ratio of PKC isoform (band density in particulate/band densities in both particulate and cytosolic fractions) of the control group was normalized to 100%, and hypoxia groups were expressed as percentages of the control group. For the quantitative analysis of PKC isoform-specific protein expressions, the optical density of each band corresponding to PKC isoforms (from whole tissue homogenate) was normalized to that of β-actin. The protein expression ratio in the control group was regarded as 100%, and data from the hypoxia groups were also expressed as percentages of the control group.

HEMATOXYLIN AND EOSIN STAINING AND IMMUNOHISTOCHEMISTRY:

The animals were anesthetized with pentobarbital sodium (50 mg/kg, i.p.) and lungs were removed from the thoracic cavity. Right lower lungs were fixed in 10% formaldehyde for at least 24 h. Paraffin slices (6 μm thickness) were stained with hematoxylin and eosin (HE) solution. HE-stained images of the slices were examined under a microscope to look for the structural changes of pulmonary artery walls in response to hypoxic exposure.

To determine the changes of PKC isoform-specific expressions in pulmonary arteries of rats after chronic hypoxia-induced pulmonary hypertension, immunostaining with cPKCα, βI, βII, γ and nPKCδ (Santa Cruz Biotechnology Inc., CA, USA) were performed as reported [27]. Lungs were infused by the fixative (3% formaldehyde in PBS) via the trachea, and then immersed in the fixative at 4°C for 24 h. The tissues were dehydrated, embedded in paraffin, and sectioned at a thickness of 5 μm. The slices were incubated with 0.3% H2O2 for 10 min to exhaust the endogenous peroxidase and washed in 0.1 M phosphate-buffered saline (PBS, pH7.4). Next, they were blocked with 10% bovine serum for 1 h. The blocked slices were incubated with primary rabbit polyclonal antibodies against cPKCα, βI, βII and γ (Santa Cruz Biotechnology Inc., CA, USA) at a dilution of 1:200 for 12 h at 4°C. The specimens were incubated in secondary antibodies of horseradish peroxidase-conjugated goat anti-rabbit IgG for 2 h. Finally, the slices were thoroughly washed in PBS, and a solution containing H2O2 (0.03%) and 3,3′-diaminobenzidine (DAB, 60%) was added to visualize the slices. Control sections were conducted the same way, but primary antibodies were omitted. The images were captured by a Leica microscope imaging system (Leica DM4000B, Wetzlar, Germany).

STATISTICAL ANALYSIS:

Quantitative analysis for immunoblotting was done after scanning of the X-ray film with Quantitative-one software (GelDoc 2000 imaging system, Bio-Rad, Hercules, CA, USA). The presented values were expressed as mean ±SE from at least 6 independent experiments. Statistical analysis was conducted by one-way analysis of variance followed by all pair-wise multiple comparison procedures using the Bonferroni test, and the significance was regarded as p<0.05.

Results

PHYSIOLOGIC ANALYSIS AND PATHOLOGIC CHANGES IN PULMONARY ARTERIES OF HYPOXIA – INDUCED PH RATS:

To confirm the establishment of hypoxia-induced PH in the rats, RVSP (a marker of systolic pulmonary arterial pressure) and the RV/(LV+S) ratio (a marker of RV hypertrophy) were measured. RVSP (mmHg) increased significantly (p<0.05 vs. 0 day 23.8±0.8, n=12) with the time of hypoxic exposure (1 d: 34.6±1.4; 3 d: 40.4±1.7; 7 d: 48.3±1.1; 14 d: 46.2±2.4; 21 d: 50.1±1.3, n=12 per group). There was also a significant increase in the RV/(LV+S) ratio (p<0.05 vs. 0 day 100%, n=12) of rats following hypoxic exposure (1 d: 111.7±8.4; 3 d: 127.8±9.3; 7 d: 133.9±10.1; 14 d: 148.7±9.8; 21 d: 156.5±8.6, n=12 per group). In addition, we also observed the pathologic changes at days 3, 7 and 21 in pulmonary arteries of rats after hypoxic exposure. There was marked vascular remodeling, including medial hypertrophy and adventitial proliferation, in both the distal and the proximal pulmonary arteries of the PH rats when compared with that of control rats. These results suggest that prolonged exposure to hypoxia can induce PH with RV hypertrophy of rats.

PKC ISOFORM-SPECIFIC EXPRESSION AND MEMBRANE TRANSLOCATION IN PULMONARY ARTERIES OF HYPOXIA-INDUCED PH RATS:

The typical Western blot results in Figure 1A showed that cPKCα (80 kDa), βI (79 kDa) and βII (79 kDa), not γ (78 kDa), presented in pulmonary arteries of rats. In addition, we found a decrease in membrane translocation of cPKCβII, but not α and βI, in pulmonary arteries of PH rats (Figures 1B and 2A). The translocation of cPKCβII from cytosolic to particulate fraction significantly decreased at 3 d (68.9±5.1%) and 7 d (90.3±5.5%) after hypoxia when compared with that of the normoxic control group (0 day 100%).

As shown in Figures 1C and 2B, cPKC isoform-specific protein levels decreased significantly during 1–14d (83.9±6.2%, 71.6±4.7%, 55.6±9.7% and 73.6±5.7%, p<0.05) for cPKCα, 1–21d (68.6±2.9%, 47.4±7.4%, 25.0±2.7%, 38.5±2.7% and 40.6±5.5%, p<0.05) for cPKCβI and 1–21d (72.1±3.1%, 41.1±2.8%, 62.4±3.2% and 72.5±5.1%, p<0.05) for cPKCβII after hypoxia when compared with that of the normoxic control group (0 day 100%).

However, we could only detect the protein expressions of nPKCδ (77.5kDa), ɛ (82kDa) and η (82kDa), but not nPKCθ and aPKCι/λ and ζ, in pulmonary arteries of rats by Western blot (Figure 3A). Unlike cPKCβII, significant increases of membrane translocations (Figures 2A and 3B) and protein expressions (Figures 2B and 3C) of nPKCδ, not ɛ and η, were observed in pulmonary arteries of rats following hypoxia exposures.

CPKC ISOFORM-SPECIFIC CELLULAR LOCALIZATION IN PULMONARY ARTERIES OF CHRONIC HYPOXIA-INDUCED HP RATS:

To further characterize the cellular localization of cPKCα, βI, βII and nPKCδ in the pulmonary arteries of hypoxia-induced PH rats, we performed immunostaining and found that the immunolabeled cPKCα, βI, βII and nPKCδ proteins were diffusely located throughout the cytoplasmic areas of pulmonary artery smooth muscle cells and fibroblasts (Figure 4A, C, E, G, n=6 per group). Furthermore, the decreased protein expressions of cPKCα, βI and βII, and the increased expression of nPKCδ could be observed at 14 d after hypoxia (Figure 4B, D, F, H, n=6 per group).

Discussion

This study reports the first description of the pattern of PKC isoform-specific membrane translocation and protein expression in pulmonary arteries of rats with hypoxia-induced PH. Assender et al. analyzed the expression of PKC isoforms in smooth muscle cells (SMC) by using Western blots and thermocycle amplification of mRNA, and demonstrated the presence of cPKCα, nPKCδ, ɛ and aPKCζ in SMC in various states of differentiation [28]. Liao et al. showed the presence of cPKCα, βI, nPKCδ, ɛ, aPKCζ in rat aortic vascular SMC using Western blot analysis [29]. cPKCα, βI and βII, nPKCδ and ɛ, and aPKCζ were reported in neonatal bovine pulmonary artery adventitial fibroblasts and pulmonary artery SMCs from chronically hypoxic neonatal calves [16,19]. In addition, the expressions of cPKCα, βII and γ, nPKCδ and ɛ, and aPKCζ were observed in ventricles of chronically hypoxic rats [30,31]. Similarly, our in vivo experiment demonstrated that 6 isoforms of cPKCα, βI and βII, nPKCδ, ɛ and η expressed in SMC and fibroblasts of rat pulmonary arteries by using Western blot and immunohistochemistry methods.

Pulmonary artery SMC and fibroblast proliferation occurs with hypoxic PH in vivo[6]. PKC is a key protein kinase cascade leading to cell proliferation in response to growth factors, hormones and antigens. However, it is not known whether PKC is involved in the signaling of hypoxia-induced pulmonary remodeling in an in vivo model. Dempsey et al. reported that the Ca2+-dependent PKC, especially cPKCα, is particularly important in hypoxia-induced pulmonary artery SMC growth and ultimately the development of chronic PH by observing the cultured pulmonary artery SMC in vitro[17,19–21]. Das et al. found that cPKCα and βII contribute to the augmented proliferative response of immature bovine pulmonary artery adventitial fibroblasts [16]. Zhu et al. reported that specific PKC isozymes mediate forskolin-induced activation of large-conductance, calcium- and voltage-activated potassium (BKCa) channels in pulmonary vascular smooth muscle (PVSM) [32]. Although investigators have reported cPKC activation in hypoxic condition, we found in this study that the decreases of cPKCβII membrane translocation and cPKCα, βI and βII protein expressions, as well as the increases of nPKCδ membrane translocation and protein expression, were involved in the development of hypoxia-induced PH of rats. These results are consistent with previous observations from in vivo cerebral ischemia and primary neuronal cultures damaged by glutamate [33,34], which suggest that decreased cPKCβII activation probably provides a negative feedback mechanism in cell hypoxic growth, and the down-regulation of cPKC isoform-specific protein expression might be linked to the augmented growth capacity of pulmonary artery SMC. Mayr et al. also reported that nPKCζ is crucial in maintaining SMC differentiation [35]. The decrease of cPKCα, βI and βII protein expressions may be the result of enhanced proteolytic degradation by Ca2+-activated proteinases during chronic hypoxia [36]. The discrepancy of studies shows the role of PKC isoform in proliferation might be cell type- and species-specific.

In this study, we also found that the development of hypoxia-induced rat PH was not accompanied by exaggerated pulmonary vascular remodeling at the early stage, suggesting that vasoconstriction is a major contributor to the increased pulmonary artery pressure. PKC activity was reported to be involved in the transduction pathway forwarding pulmonary vasoconstriction in response to alveolar hypoxia [37], but which PKC isoform is responsible for vasoconstriction is unclear. Dempsey et al. demonstrated that nPKCɛ-null mice have decreased hypoxic pulmonary vasoconstriction (HPV) [38]; the Ca2+-independent vascular contraction appears to be associated with plasmalemmal translocation of nPKCɛ [39]. Our finding of increased nPKCδ membrane translocation and protein expression in pulmonary arteries of hypoxia-induced PH rats is consistent with the observation that nPKCδ was involved in modulating contraction via actions on the myofilaments [13]. These data show that the different PKC isoforms appear to have distinct functions regarding phosphorylation of specific substrate proteins such as cell proliferation and vasoconstriction.

Conclusions

In conclusion, our study is the first to demonstrate the PKC isoform-specific membrane translocation and protein expression systematically in a preparation of a whole animal model of hypoxia-induced rat PH. The present results indicate that the changes in membrane translocation and protein expression of cPKCα, βI, βII and nPKCδ are involved in the development of hypoxia-induced rat PH. Future experiments will focus on evaluating the PKC isoform-specific role in pulmonary artery constriction and proliferation.

References

1. Archer S, Rich S, Primary pulmonary hypertension: a vascular biology and translational research “Work in progress”: Circulation, 2000; 102; 2781-91, pmid: 11094047

2. Runo JR, Loyd JE, Primary pulmonary hypertension: Lancet, 2003; 361; 1533-44, pmid: 12737878

3. Beghetti M, Spahr-Schopfer I, Mensi N, Effects of inhaled nitric oxide and intravenous magnesium sulphate, alone and in combination, in a porcine model of hypoxic pulmonary hypertension: Med Sci Monit, 2003; 9; BR193-98, pmid: 12824941

4. Stenmark KR, Mecham RP, Cellular and molecular mechanisms of pulmonary vascular remodeling: Annu Rev Physiol, 1997; 59; 89-144, pmid: 9074758

5. Jeffery TK, Wanstall JC, Pulmonary vascular remodeling: a target for therapeutic intervention in pulmonary hypertension: Pharmacol Ther, 2001; 92; 1-20, pmid: 11750034

6. Hayashida K, Fujita J, Miyake Y, Bone marrow-derived cells contribute to pulmonary vascular remodeling in hypoxia-induced pulmonary hypertension: Chest, 2005; 127; 1793-98, pmid: 15888860

7. Chassagne C, Eddahibi S, Adamy C, Modulation of angiotensin II receptor expression during development and regression of hypoxic pulmonary hypertension: Am J Respir Cell Mol Biol, 2000; 22; 323-32, pmid: 10696069

8. Littler CM, Wehling CA, Wick MJ, Divergent contractile and structural responses of the murine PKC-epsilon null pulmonary circulation to chronic hypoxia: Am J Physiol Lung Cell Mol Physiol, 2005; 289; L1083-93, pmid: 16085670

9. Nishizuka Y, Protein kinase C and lipid signaling for sustained cellular responses: FASEB J, 1995; 9; 484-96, pmid: 7737456

10. Newton AC, Protein kinase C: structure, function, and regulation: J Biol Chem, 1995; 270; 28495-98, pmid: 7499357

11. Barnett ME, Madgwick DK, Takemoto DJ, Protein kinase C as a stress sensor: Cell Signal, 2007; 19; 1820-29, pmid: 17629453

12. Barman SA, Zhu S, White RE, Protein kinase C inhibits BKCa channel activity in pulmonary arterial smooth muscle: Am J Physiol Lung Cell Mol Physiol, 2004; 286; L149-55, pmid: 14514518

13. Damron DS, Nadim HS, Hong SJ, Intracellular translocation of PKC isoforms in canine pulmonary artery smooth muscle cells by ANG II: Am J Physiol, 1998; 274; L278-88, pmid: 9486214

14. Kurkinen K, Busto R, Goldsteins G, Isoform-specific membrane translocation of protein kinase C after ischemic preconditioning: Neurochem Res, 2001; 26; 1139-44, pmid: 11700956

15. Niu C, Li J, Cui X, Changes in cPKC isoform-specific membrane translocation and protein expression in the brain of hypoxic preconditioned mice: Neurosci Lett, 2005; 384; 1-6, pmid: 15927373

16. Das M, Stenmark KR, Ruff LJ, Dempsey EC, Selected isozymes of PKC contribute to augmented growth of fetal and neonatal bovine PA adventitial fibroblasts: Am J Physiol, 1997; 273; L1276-84, pmid: 9435584

17. Dempsey EC, Badesch DB, Dobyns EL, Stenmark KR: J Cell Physiol, 1994; 160; 469-81, pmid: 8077285

18. Shimoda LA, Sham JS, Sylvester JT, Altered pulmonary vasoreactivity in the chronically hypoxic lung: Physiol Res, 2000; 49; 549-60, pmid: 11191359

19. Xu Y, Stenmark KR, Das M, Pulmonary artery smooth muscle cells from chronically hypoxic neonatal calves retain fetal-like and acquire new growth properties: Am J Physiol, 1997; 273; L234-45, pmid: 9252561

20. Dempsey EC, McMurtry IF, O’Brien RF, Protein kinase C activation allows pulmonary artery smooth muscle cells to proliferate to hypoxia: Am J Physiol, 1991; 260; L136-45, pmid: 1996657

21. Dempsey EC, Frid MG, Aldashev AA, Heterogeneity in the proliferative response of bovine pulmonary artery smooth muscle cells to mitogens and hypoxia: importance of protein kinase C: Can J Physiol Pharmacol, 1997; 75; 936-44, pmid: 9315363

22. Das M, Dempsey EC, Bouchey D, Chronic hypoxia induces exaggerated growth responses in pulmonary artery adventitial fibroblasts: potential contribution of specific protein kinase c isozymes: Am J Respir Cell Mol Biol, 2000; 22; 15-25, pmid: 10615061

23. Short MD, Fox SM, Lam CF, Protein kinase Czeta attenuates hypoxia-induced proliferation of fibroblasts by regulating MAP kinase phosphatase-1 expression: Mol Biol Cell, 2006; 17; 1995-2008, pmid: 16467381

24. Christou H, Morita T, Hsieh CM, Prevention of hypoxia-induced pulmonary hypertension by enhancement of endogenous heme oxygenase-1 in the rat: Circ Res, 2000; 86; 1224-29, pmid: 10864912

25. Deten A, Millar H, Zimmer HG, Catheterization of pulmonary artery in rats with an ultraminiature catheter pressure transducer: Am J Physiol Heart Circ Physiol, 2003; 285; H2212-17, pmid: 12881215

26. Li J, Niu C, Han S, Identification of protein kinase C isoforms involved in cerebral hypoxic preconditioning of mice: Brain Res, 2005; 1060; 62-72, pmid: 16214117

27. Ding J, Ding N, Wang N, Determination of conventional protein kinase C isoforms involved in high intraocular pressure-induced retinal ischemic preconditioning of rats: Vision Res, 2009; 49; 315-21, pmid: 19013479

28. Assender JW, Kontny E, Fredholm BB, Expression of protein kinase C isoforms in smooth muscle cells in various states of differentiation: FEBS Lett, 1994; 342; 76-80, pmid: 8143854

29. Liao DF, Monia B, Dean N, Berk BC, Protein kinase C-zeta mediates angiotensin II activation of ERK1/2 in vascular smooth muscle cells: J Biol Chem, 1997; 272; 6146-50, pmid: 9045626

30. Uenoyama M, Ogata S, Nakanishi K, Protein kinase C mRNA and protein expressions in hypobaric hypoxia-induced cardiac hypertrophy in rats: Acta Physiol (Oxf), 2010; 198; 431-40, pmid: 19995357

31. Morel OE, Buvry A, Le CP, Effects of nifedipine-induced pulmonary vasodilatation on cardiac receptors and protein kinase C isoforms in the chronically hypoxic rat: Pflugers Arch, 2003; 446; 356-64, pmid: 12715180

32. Zhu S, White RE, Barman SA, Effect of PKC isozyme inhibition on forskolin-induced activation of BKCa channels in rat pulmonary arterial smooth muscle: Lung, 2006; 184; 89-97, pmid: 16622778

33. Chakravarthy BR, Wang J, Tremblay R: Cell Signal, 1998; 10; 291-95, pmid: 9617487

34. Durkin JP, Tremblay R, Chakravarthy B, Evidence that the early loss of membrane protein kinase C is a necessary step in the excitatory amino acid-induced death of primary cortical neurons: J Neurochem, 1997; 68; 1400-12, pmid: 9084410

35. Mayr M, Siow R, Chung YL, Proteomic and metabolomic analysis of vascular smooth muscle cells: role of PKCdelta: Circ Res, 2004; 94; e87-96, pmid: 15131007

36. Louis JC, Magal E, Brixi A, Reduction of protein kinase C activity in the adult rat brain following transient forebrain ischemia: Brain Res, 1991; 541; 171-74, pmid: 2029620

37. Weissmann N, Voswinckel R, Hardebusch T, Evidence for a role of protein kinase C in hypoxic pulmonary vasoconstriction: Am J Physiol, 1999; 276; L90-95, pmid: 9887060

38. Littler CM, Morris KG, Fagan KA, Protein kinase C-epsilon-null mice have decreased hypoxic pulmonary vasoconstriction: Am J Physiol Heart Circ Physiol, 2003; 284; H1321-31, pmid: 12505875

39. Khalil RA, Lajoie C, Resnick MS, Morgan KG, Ca(2+)-independent isoforms of protein kinase C differentially translocate in smooth muscle: Am J Physiol, 1992; 263; C714-19, pmid: 1415520

In Press

Clinical Research  

Institutional and Regional Variations in Access to Clinical Trials and Next-Generation Sequencing in Turkis...

Med Sci Monit In Press; DOI: 10.12659/MSM.951027  

Clinical Research  

Low-Intensity Blood Flow-Restricted Multi-Joint Exercise Improves Muscle Function in Patients With Patellof...

Med Sci Monit In Press; DOI: 10.12659/MSM.950516  

Review article  

Musculoskeletal Ultrasound and MRI in the Evaluation of Chemotherapy-Induced Peripheral Neuropathy: A Review

Med Sci Monit In Press; DOI: 10.12659/MSM.951283  

Clinical Research  

Sensory Processing, Dissociation, and Affective Symptoms in Misophonia: A Cross-Sectional Study of 35 Adults

Med Sci Monit In Press; DOI: 10.12659/MSM.950938  

Most Viewed Current Articles

17 Jan 2024 : Review article   10,187,196

Vaccination Guidelines for Pregnant Women: Addressing COVID-19 and the Omicron Variant

DOI :10.12659/MSM.942799

Med Sci Monit 2024; 30:e942799

0:00

13 Nov 2021 : Clinical Research   3,708,487

Acceptance of COVID-19 Vaccination and Its Associated Factors Among Cancer Patients Attending the Oncology ...

DOI :10.12659/MSM.932788

Med Sci Monit 2021; 27:e932788

0:00

14 Dec 2022 : Clinical Research   2,341,643

Prevalence and Variability of Allergen-Specific Immunoglobulin E in Patients with Elevated Tryptase Levels

DOI :10.12659/MSM.937990

Med Sci Monit 2022; 28:e937990

0:00

16 May 2023 : Clinical Research   706,524

Electrophysiological Testing for an Auditory Processing Disorder and Reading Performance in 54 School Stude...

DOI :10.12659/MSM.940387

Med Sci Monit 2023; 29:e940387

0:00

Your Privacy

We use cookies to ensure the functionality of our website, to personalize content and advertising, to provide social media features, and to analyze our traffic. If you allow us to do so, we also inform our social media, advertising and analysis partners about your use of our website, You can decise for yourself which categories you you want to deny or allow. Please note that based on your settings not all functionalities of the site are available. View our privacy policy.

Medical Science Monitor eISSN: 1643-3750
Medical Science Monitor eISSN: 1643-3750